For prospective immunotherapeutic applications, TCRγδ cells have some advantages: their restricted TCR repertoire and lack of recognition of MHC/peptide complexes, precludes their propensity to induce GVHD in the allogeneic setting. Here, HLA-C is linked to graft versus host disease.